These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Prospects of cell therapy for disorders of myelin. Ben-Hur T; Goldman SA Ann N Y Acad Sci; 2008 Oct; 1142():218-49. PubMed ID: 18990129 [TBL] [Abstract][Full Text] [Related]
43. Axonal damage in multiple sclerosis. Haines JD; Inglese M; Casaccia P Mt Sinai J Med; 2011; 78(2):231-43. PubMed ID: 21425267 [TBL] [Abstract][Full Text] [Related]
44. Remyelination in multiple sclerosis: a challenge for therapy. The 1996 European Charcot Foundation Lecture. Compston A Mult Scler; 1997 Apr; 3(2):51-70. PubMed ID: 9291155 [No Abstract] [Full Text] [Related]
45. No quiet surrender: molecular guardians in multiple sclerosis brain. Steinman L J Clin Invest; 2015 Apr; 125(4):1371-8. PubMed ID: 25831441 [TBL] [Abstract][Full Text] [Related]
46. Physiopathology of symptoms and signs in multiple sclerosis. Sá MJ Arq Neuropsiquiatr; 2012 Sep; 70(9):733-40. PubMed ID: 22990733 [TBL] [Abstract][Full Text] [Related]
47. Multiple sclerosis. Compston A; Coles A Lancet; 2008 Oct; 372(9648):1502-17. PubMed ID: 18970977 [TBL] [Abstract][Full Text] [Related]
48. Progress in determining the causes and treatment of multiple sclerosis. Noseworthy JH Nature; 1999 Jun; 399(6738 Suppl):A40-7. PubMed ID: 10392579 [TBL] [Abstract][Full Text] [Related]
49. A function of myelin is to protect axons from subsequent injury: implications for deficits in multiple sclerosis. Rodriguez M Brain; 2003 Apr; 126(Pt 4):751-2. PubMed ID: 12615635 [No Abstract] [Full Text] [Related]
54. Gut response. Therapy with ingested immunomodulatory proteins. Brod SA Arch Neurol; 1997 Oct; 54(10):1300-2. PubMed ID: 9341578 [TBL] [Abstract][Full Text] [Related]
55. Remyelination in Multiple Sclerosis. Proceedings of the European Charcot Foundation Symposium. Vienna, Austria, 4-6 July 1996. Mult Scler; 1997 Apr; 3(2):51-169. PubMed ID: 9324422 [No Abstract] [Full Text] [Related]
56. Multiple sclerosis in its European matrix: some aspects of history, mechanisms and treatment. McDonald I Can J Neurol Sci; 2004 Feb; 31(1):37-47. PubMed ID: 15038469 [TBL] [Abstract][Full Text] [Related]
57. Limiting and repairing the damage in multiple sclerosis. Compston A J Neurol Neurosurg Psychiatry; 1991 Nov; 54(11):945-8. PubMed ID: 1800662 [No Abstract] [Full Text] [Related]